Literature DB >> 22623769

Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.

Xianming Yu1, Patrick J McCarthy, Zhenxun Wang, Daniel A Gorlen, Janet E Mertz.   

Abstract

The BZLF1 gene controls the switch between latent and lytic infection by Epstein-Barr virus (EBV). We previously reported that both the ZV and ZIIR elements within the BZLF1 promoter, Zp, are potent transcription silencers within the context of an intact EBV genome. We report here identification of another sequence element, ZV', which synergized with ZV in repressing Zp via binding ZEB1 or ZEB2. We then determined the phenotype of a variant of EBV strain B95.8 in which the ZV, ZV', and ZIIR elements were concurrently mutated. HEK293 cell lines infected with this triple mutant (tmt) virus spontaneously synthesized 6- to 10-fold more viral BZLF1, BRLF1, BMRF1, and BLLF1 RNAs, 3- to 6-fold more viral Zta, Rta, and EAD proteins, 3- to 5-fold more viral DNA, and 7- to 9-fold more infectious virus than did 293 cell lines latently infected with either the ZV ZV' double mutant (dmt) or ZIIR mutant (mt) virus. While ZV ZV' ZIIR tmt EBV efficiently infected human primary blood B cells in vitro, it was highly defective in immortalizing them. Instead of the nearly complete silencing of BZLF1 gene expression that occurs within 4 days after primary infection with wild-type EBV, the ZV ZV' ZIIR tmt-infected cells continued to synthesize BZLF1 RNA, with 90% of them dying within 9 days postinfection. BL41 cells infected with this "superlytic" virus also exhibited increased synthesis of BZLF1 and BMRF1 RNAs. Thus, we conclude that the ZV, ZV', and ZIIR silencing elements act synergistically to repress transcription from Zp, thereby tightly controlling BZLF1 gene expression, which is crucial for establishing and maintaining EBV latency.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22623769      PMCID: PMC3421699          DOI: 10.1128/JVI.00234-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  ZEB negatively regulates the lytic-switch BZLF1 gene promoter of Epstein-Barr virus.

Authors:  Richard J Kraus; Jacqueline G Perrigoue; Janet E Mertz
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6.

Authors:  L Flamand; J Menezes
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma.

Authors:  Julie L Ryan; Hongxin Fan; Sally L Glaser; Steven A Schichman; Nancy Raab-Traub; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

6.  Epstein-Barr virus BZLF1 gene is activated by transforming growth factor-beta through cooperativity of Smads and c-Jun/c-Fos proteins.

Authors:  Chih-Lung Liang; Jo-Lin Chen; Yun-Pung Paul Hsu; Jonathan T Ou; Yu-Sun Chang
Journal:  J Biol Chem       Date:  2002-04-23       Impact factor: 5.157

7.  Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency.

Authors:  Helen Bryant; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma.

Authors:  Jia Junying; Kathrin Herrmann; Gillian Davies; David Lissauer; Andrew Bell; Judith Timms; Gary M Reynolds; Stefan G Hubscher; Lawrence S Young; Gerald Niedobitek; Paul G Murray
Journal:  Virology       Date:  2003-02-15       Impact factor: 3.616

9.  CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs during induction of the EBV lytic cycle.

Authors:  Frederick Y Wu; Shizhen Emily Wang; Honglin Chen; Ling Wang; S Diane Hayward; Gary S Hayward
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  The BZLF1 promoter of Epstein-Barr virus is controlled by E box-/HI-motif-binding factors during virus latency.

Authors:  Cornelia Thomas; Arnd Dankesreiter; Hans Wolf; Fritz Schwarzmann
Journal:  J Gen Virol       Date:  2003-04       Impact factor: 3.891

View more
  9 in total

1.  An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Authors:  Shi-Dong Ma; Xianming Yu; Janet E Mertz; Jenny E Gumperz; Erik Reinheim; Ying Zhou; Weihua Tang; William J Burlingham; Margaret L Gulley; Shannon C Kenney
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 2.  Regulation of the latent-lytic switch in Epstein-Barr virus.

Authors:  Shannon C Kenney; Janet E Mertz
Journal:  Semin Cancer Biol       Date:  2014-01-20       Impact factor: 15.707

Review 3.  Proteins and Proteoforms: New Separation Challenges.

Authors:  Fred E Regnier; JinHee Kim
Journal:  Anal Chem       Date:  2017-12-18       Impact factor: 6.986

4.  Activation and repression of Epstein-Barr Virus and Kaposi's sarcoma-associated herpesvirus lytic cycles by short- and medium-chain fatty acids.

Authors:  Kelly L Gorres; Derek Daigle; Sudharshan Mohanram; George Miller
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

5.  Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.

Authors:  Lou-Ella M M Alexander; January Watters; Jessica A Reusch; Michelle Maurin; Brook S Nepon-Sixt; Katerina Vrzalikova; Mark G Alexandrow; Paul G Murray; Kenneth L Wright
Journal:  Mol Immunol       Date:  2017-08-31       Impact factor: 4.407

6.  KRAB-ZFP Repressors Enforce Quiescence of Oncogenic Human Herpesviruses.

Authors:  Xiaofan Li; Eric M Burton; Siva Koganti; Jizu Zhi; Francis Doyle; Scott A Tenenbaum; Biljana Horn; Sumita Bhaduri-McIntosh
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

7.  Proteomics and Transcriptomics of BJAB Cells Expressing the Epstein-Barr Virus Noncoding RNAs EBER1 and EBER2.

Authors:  Genaro Pimienta; Victor Fok; Maria Haslip; Maria Nagy; Seyedtaghi Takyar; Joan A Steitz
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

8.  A cancer-associated Epstein-Barr virus BZLF1 promoter variant enhances lytic infection.

Authors:  Jillian A Bristol; Reza Djavadian; Emily R Albright; Carrie B Coleman; Makoto Ohashi; Mitchell Hayes; James C Romero-Masters; Elizabeth A Barlow; Paul J Farrell; Rosemary Rochford; Robert F Kalejta; Eric C Johannsen; Shannon C Kenney
Journal:  PLoS Pathog       Date:  2018-07-27       Impact factor: 6.823

9.  Data supporting the functional role of Eleven-nineteen Lysine-rich Leukemia 3 (ELL3) in B cell lymphoma cell line cells.

Authors:  Lou-Ella M M Alexander; January Watters; Jessica A Reusch; Michelle Maurin; Brook S Nepon-Sixt; Katerina Vrzalikova; Mark G Alexandrow; Paul G Murray; Kenneth L Wright
Journal:  Data Brief       Date:  2017-09-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.